tiprankstipranks
Trending News
More News >
Stryker Corporation (SYK)
NYSE:SYK
US Market

Stryker (SYK) Earnings Dates, Call Summary & Reports

Compare
2,591 Followers

Earnings Data

Report Date
May 06, 2026
After Close (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
3
Last Year’s EPS
2.84
Same Quarter Last Year
Based on 21 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Jan 29, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call emphasized broad-based revenue and earnings strength, record robotics momentum (Mako 4 and installed base >3,000), strong cash generation, and continued margin expansion, while also acknowledging manageable near-term headwinds including tariffs (~$400M in 2026), higher interest expense, competitive pressure in parts of vascular, and some regional capital softness. Guidance for 2026 is constructive (8.0%–9.5% organic growth and $14.90–$15.10 adjusted EPS) and management highlighted operational levers and M&A firepower to support growth.
Company Guidance
Stryker guided 2026 organic net sales growth of 8.0%–9.5% and adjusted net EPS of $14.90–$15.10, expecting a modestly positive impact from price and a slightly favorable FX effect if rates hold; management sees the same number of selling days and similar seasonality to 2025, anticipates a full‑year tariff headwind of about $400 million (including an incremental ~$200 million realized in H1), forecasts adjusted other income/expense of roughly $420 million, targets an effective tax rate of 15%–16%, and continues to aim for free cash flow conversion of about 70%–80% of adjusted net earnings under its long‑range plan.
Strong Top-Line Growth
Organic sales growth of 11.0% in Q4 and 10.3% for full-year 2025, with total sales surpassing $25 billion; U.S. full-year organic growth of 11.2% and international organic growth of 7.5%.
Segment Outperformance — MedSurg & Neurotechnology
MedSurg & Neurotechnology delivered exceptional Q4 organic growth of 12.6% (U.S. +13.0%, International +10.9%), driven by instruments, endoscopy, and medical product strength.
Instruments and Endoscopy Momentum
Instruments U.S. organic sales up 19.1% (high-teens growth across orthopedic instruments and Surgical Technologies); Endoscopy U.S. organic sales up 11.1% led by sustainability and sports medicine camera/platform adoption.
Robotics Leadership and Mako 4 Performance
Record quarter of Mako installations; installed base topped >3,000 worldwide. U.S. utilization: over two-thirds of knees and over one-third of hips on Mako; global utilization ~50% knees and >20% hips. New applications and Mako 4 drove strong adoption and utilization gains.
Orthopaedics Growth and New Product Momentum
Orthopaedics organic growth 8.4% (U.S. +9.6%, International +5.4%). Notable: U.S. knees +7.6%, U.S. hips +5.6%, Trauma & Extremities U.S. +8.5%, and U.S. Other ortho +28.7% driven by Mako 4 installations and recent launches (e.g., Triathlon Gold limited launch).
Earnings, Margin Expansion, and Profitability
Q4 adjusted EPS $4.47 (+11.5% YoY) and full-year adjusted EPS $13.63 (+11.8% YoY). Adjusted operating margin expanded to 30.2% (100 basis points improvement YoY); second consecutive year of ≥100 bps adjusted operating margin expansion.
Strong Cash Flow and Balance Sheet
Year-to-date cash from operations of $5.0 billion, up $820 million YoY; free cash flow as % of adjusted net earnings 81% vs 75% prior year (target range 70–80%). Management signals continued M&A firepower from strong financial position.
Constructive 2026 Guidance and Market Outlook
Provided 2026 guidance of organic net sales growth of 8.0%–9.5% and adjusted net EPS of $14.90–$15.10; management expects sustained procedural volumes, healthy hospital CapEx and an elevated capital order book entering 2026.

Stryker (SYK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SYK Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 06, 2026
2026 (Q1)
3.00 / -
2.84
Jan 29, 2026
2025 (Q4)
4.40 / 4.47
4.0111.47% (+0.46)
Oct 30, 2025
2025 (Q3)
3.13 / 3.19
2.8711.15% (+0.32)
Jul 31, 2025
2025 (Q2)
3.07 / 3.13
2.8111.39% (+0.32)
May 01, 2025
2025 (Q1)
2.71 / 2.84
2.513.60% (+0.34)
Jan 28, 2025
2024 (Q4)
3.87 / 4.01
3.4615.90% (+0.55)
Oct 29, 2024
2024 (Q3)
2.77 / 2.87
2.4616.67% (+0.41)
Jul 30, 2024
2024 (Q2)
2.79 / 2.81
2.5410.63% (+0.27)
Apr 30, 2024
2024 (Q1)
2.36 / 2.50
2.1416.82% (+0.36)
Jan 30, 2024
2023 (Q4)
3.27 / 3.46
315.33% (+0.46)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SYK Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jan 29, 2026
$354.30$369.56+4.31%
Oct 30, 2025
$368.98$356.24-3.45%
Jul 31, 2025
$391.84$376.93-3.81%
May 01, 2025
$372.34$376.56+1.13%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Stryker Corporation (SYK) report earnings?
Stryker Corporation (SYK) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
    What is Stryker Corporation (SYK) earnings time?
    Stryker Corporation (SYK) earnings time is at May 06, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SYK EPS forecast?
          SYK EPS forecast for the fiscal quarter 2026 (Q1) is 3.